Lilly says exploratory Taltz-Zepbound data broaden biomarker changes

Eli Lilly said exploratory Phase 3b data from the TOGETHER-PsO study showed broader biomarker changes with Taltz and Zepbound than with Taltz alone in adults with psoriasis and obesity. The company said the findings add to previously reported results on skin clearance and weight reduction.